M&T Bank Corp Lowers Position in Danaher Corporation $DHR

M&T Bank Corp trimmed its position in Danaher Corporation (NYSE:DHR) by 78.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 92,179 shares of the conglomerate’s stock after selling 340,604 shares during the period. M&T Bank Corp’s holdings in Danaher were worth $21,102,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. JPL Wealth Management LLC purchased a new position in Danaher during the third quarter valued at $25,000. Elevated Capital Advisors LLC purchased a new stake in shares of Danaher in the 4th quarter worth about $26,000. WFA of San Diego LLC bought a new position in shares of Danaher in the 2nd quarter worth about $26,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Danaher in the 3rd quarter worth about $27,000. Finally, TruNorth Capital Management LLC purchased a new position in Danaher during the 3rd quarter valued at about $28,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 2.9%

NYSE:DHR opened at $178.72 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.51 and a current ratio of 1.87. The firm has a market cap of $126.49 billion, a P/E ratio of 34.57, a P/E/G ratio of 2.50 and a beta of 0.95. Danaher Corporation has a fifty-two week low of $175.00 and a fifty-two week high of $242.80. The firm has a 50-day simple moving average of $196.45 and a two-hundred day simple moving average of $214.10.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the prior year, the firm posted $1.88 earnings per share. The business’s revenue was up 3.7% on a year-over-year basis. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. Analysts predict that Danaher Corporation will post 8.4 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Friday, March 27th will be given a $0.40 dividend. This is a boost from Danaher’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Friday, March 27th. This represents a $1.60 annualized dividend and a yield of 0.9%. Danaher’s payout ratio is currently 30.95%.

Insider Buying and Selling

In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total transaction of $274,573.20. Following the sale, the executive vice president directly owned 5,099 shares in the company, valued at approximately $1,060,642.99. This trade represents a 20.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on DHR shares. Wells Fargo & Company dropped their price objective on shares of Danaher from $240.00 to $212.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Evercore lifted their target price on shares of Danaher from $225.00 to $232.00 and gave the company an “outperform” rating in a report on Tuesday. Wolfe Research dropped their price target on Danaher from $260.00 to $230.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Leerink Partners upped their price target on Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a research note on Friday, January 16th. Finally, JPMorgan Chase & Co. reduced their price objective on Danaher from $275.00 to $245.00 and set an “overweight” rating for the company in a research report on Wednesday. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $242.45.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and slight raise to FY EPS range — Danaher beat non‑GAAP EPS estimates ($2.06 vs. consensus) and nudged full‑year adjusted EPS guidance higher, which supports earnings visibility. Earnings Call Highlights
• Positive Sentiment: Bioprocessing momentum and M&A strategy remain drivers — management highlighted strength in bioprocessing and the acquisition pipeline as long‑term growth levers. Q1 Deep Dive
• Neutral Sentiment: Large euro‑denominated senior‑notes offering (~€2.98B net proceeds) — the deal finances operations and transactions but increases liabilities; market reaction depends on how proceeds are used. Notes Offering
• Neutral Sentiment: Masimo acquisition: longer‑term optionality vs. near‑term integration/earnings pressure — analysts note the deal adds strategic upside but may weigh on near‑term returns and capital allocation. Masimo Analysis
• Negative Sentiment: $172.5M shareholder settlement over post‑pandemic demand disclosures — a material cash charge and reputational headwind that increases near‑term litigation/expense risk. Settlement Report
• Negative Sentiment: Revenue miss and Diagnostics softness weighed on the print — core revenue growth was modest and Diagnostics showed weakness (lighter respiratory season at Cepheid), which undercut the EPS beat. Revenue/Segment Notes
• Negative Sentiment: Multiple analyst price‑target cuts (Morgan Stanley, JPMorgan, Wells Fargo, Guggenheim, UBS among others) — downgrades and lower targets increase downside pressure and reduce near‑term analyst support. Morgan Stanley PT Cut

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.